A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection.
Counoupas, C
Johansen, MD
Stella, AO
Nguyen, DH
Ferguson, AL
Aggarwal, A
Bhattacharyya, ND
Grey, A
Hutchings, O
Patel, K
Siddiquee, R
Stewart, EL
Feng, CG
Hansbro, NG
Palendira, U
Steain, MC
Saunders, BM
Low, JKK
Mackay, JP
Kelleher, AD
Britton, WJ
Turville, SG
Hansbro, PM
Triccas, JA
- Publisher:
- Springer Science and Business Media LLC
- Publication Type:
- Journal Article
- Citation:
- NPJ Vaccines, 2021, 6, (1), pp. 143
- Issue Date:
- 2021-11-30
Recently Added
Filename | Description | Size | |||
---|---|---|---|---|---|
s41541-021-00406-4.pdf | Published version | 1.7 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is new to OPUS and is not currently available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Counoupas, C | |
dc.contributor.author | Johansen, MD | |
dc.contributor.author | Stella, AO | |
dc.contributor.author | Nguyen, DH | |
dc.contributor.author | Ferguson, AL | |
dc.contributor.author | Aggarwal, A | |
dc.contributor.author | Bhattacharyya, ND | |
dc.contributor.author | Grey, A | |
dc.contributor.author | Hutchings, O | |
dc.contributor.author | Patel, K | |
dc.contributor.author | Siddiquee, R | |
dc.contributor.author | Stewart, EL | |
dc.contributor.author | Feng, CG | |
dc.contributor.author | Hansbro, NG | |
dc.contributor.author | Palendira, U | |
dc.contributor.author | Steain, MC | |
dc.contributor.author | Saunders, BM | |
dc.contributor.author | Low, JKK | |
dc.contributor.author | Mackay, JP | |
dc.contributor.author | Kelleher, AD | |
dc.contributor.author | Britton, WJ | |
dc.contributor.author | Turville, SG | |
dc.contributor.author | Hansbro, PM | |
dc.contributor.author | Triccas, JA | |
dc.date.accessioned | 2022-01-07T01:53:29Z | |
dc.date.available | 2021-11-03 | |
dc.date.available | 2022-01-07T01:53:29Z | |
dc.date.issued | 2021-11-30 | |
dc.identifier.citation | NPJ Vaccines, 2021, 6, (1), pp. 143 | |
dc.identifier.issn | 2059-0105 | |
dc.identifier.issn | 2059-0105 | |
dc.identifier.uri | http://hdl.handle.net/10453/152805 | |
dc.description.abstract | Global control of COVID-19 requires broadly accessible vaccines that are effective against SARS-CoV-2 variants. In this report, we exploit the immunostimulatory properties of bacille Calmette-Guérin (BCG), the existing tuberculosis vaccine, to deliver a vaccination regimen with potent SARS-CoV-2-specific protective immunity. Combination of BCG with a stabilised, trimeric form of SARS-CoV-2 spike antigen promoted rapid development of virus-specific IgG antibodies in the blood of vaccinated mice, that was further augmented by the addition of alum. This vaccine formulation, BCG:CoVac, induced high-titre SARS-CoV-2 neutralising antibodies (NAbs) and Th1-biased cytokine release by vaccine-specific T cells, which correlated with the early emergence of T follicular helper cells in local lymph nodes and heightened levels of antigen-specific plasma B cells after vaccination. Vaccination of K18-hACE2 mice with a single dose of BCG:CoVac almost completely abrogated disease after SARS-CoV-2 challenge, with minimal inflammation and no detectable virus in the lungs of infected animals. Boosting BCG:CoVac-primed mice with a heterologous vaccine further increased SARS-CoV-2-specific antibody responses, which effectively neutralised B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern. These findings demonstrate the potential for BCG-based vaccination to protect against major SARS-CoV-2 variants circulating globally. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation | http://purl.org/au-research/grants/nhmrc/1175134 | |
dc.relation | http://purl.org/au-research/grants/nhmrc/1153493 | |
dc.relation.ispartof | NPJ Vaccines | |
dc.relation.isbasedon | 10.1038/s41541-021-00406-4 | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. | |
dc.title | A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. | |
dc.type | Journal Article | |
utslib.citation.volume | 6 | |
utslib.location.activity | England | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
utslib.copyright.status | recently_added | * |
dc.date.updated | 2022-01-07T01:53:28Z | |
pubs.issue | 1 | |
pubs.publication-status | Published online | |
pubs.volume | 6 | |
utslib.citation.issue | 1 |
Abstract:
Global control of COVID-19 requires broadly accessible vaccines that are effective against SARS-CoV-2 variants. In this report, we exploit the immunostimulatory properties of bacille Calmette-Guérin (BCG), the existing tuberculosis vaccine, to deliver a vaccination regimen with potent SARS-CoV-2-specific protective immunity. Combination of BCG with a stabilised, trimeric form of SARS-CoV-2 spike antigen promoted rapid development of virus-specific IgG antibodies in the blood of vaccinated mice, that was further augmented by the addition of alum. This vaccine formulation, BCG:CoVac, induced high-titre SARS-CoV-2 neutralising antibodies (NAbs) and Th1-biased cytokine release by vaccine-specific T cells, which correlated with the early emergence of T follicular helper cells in local lymph nodes and heightened levels of antigen-specific plasma B cells after vaccination. Vaccination of K18-hACE2 mice with a single dose of BCG:CoVac almost completely abrogated disease after SARS-CoV-2 challenge, with minimal inflammation and no detectable virus in the lungs of infected animals. Boosting BCG:CoVac-primed mice with a heterologous vaccine further increased SARS-CoV-2-specific antibody responses, which effectively neutralised B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern. These findings demonstrate the potential for BCG-based vaccination to protect against major SARS-CoV-2 variants circulating globally.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph